News

Three-dimensional (3D) breast screens (mammograms) could offer substantial improvements in cancer detection and reducing false positives when used in conjunction with traditional two-dimensional (2D) mammograms, according to the results of a new study published in The Lancet Oncology.

Women with triple-negative breast cancer are more likely to have high levels of the MET biomarker in their tumours, making it a good new target for cancer drugs according to research published in the British Journal of Cancer, today (Wednesday).

A study that compared the benefits and harms of the frequency of screening mammography to age, breast density and postmenopausal use of hormone therapy (HT) suggests that woman aged 50 to 74 years who undergo biennial screenings have a similar risk of advanced-stage disease and a lower cumulative risk of false-positive results than those who get mammograms annually, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

Breast tumour DNA circulating in the bloodstream could be used to measure how well a woman’s cancer is responding to treatment, according to a new Cancer Research UK study published in the New England Journal of Medicine.

Genetic errors driving the majority of breast cancers may be caused by a hyperactive enzyme called APOBEC3B, according to US researchers.